Neuphoria Therapeutics (NASDAQ:NEUP) vs. Moderna (NASDAQ:MRNA) Financial Comparison

Moderna (NASDAQ:MRNA – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Profitability

This table compares Moderna and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.3% of Moderna shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Moderna and Neuphoria Therapeutics, as reported by MarketBeat.com.

Moderna presently has a consensus target price of $76.72, indicating a potential downside of 50.45%. Neuphoria Therapeutics has a consensus target price of $7.00, indicating a potential upside of 84.94%. Given Neuphoria Therapeutics’ higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Moderna.

Valuation & Earnings

This table compares Moderna and Neuphoria Therapeutics”s gross revenue, earnings per share and valuation.

Neuphoria Therapeutics has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Moderna has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.

Summary

Moderna beats Neuphoria Therapeutics on 10 of the 14 factors compared between the two stocks.

About Moderna

(Get Free Report)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.